Page last updated: 2024-12-11

diacetylmonoxime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diacetylmonoxime: used diagnostically for determining urea in blood; structure; myosin ATPase antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diacetylmonoxime : A ketoxime obtained via formal condensation of butane-2,3-dione with hydroxylamine. It is a reversible myosin ATPase inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6409633
CHEMBL ID1255578
CHEBI ID4480
SCHEMBL ID282899
SCHEMBL ID257234
MeSH IDM0045870

Synonyms (99)

Synonym
2,3-butanedione, monooxime
HSCI1_000099
EU-0100090
CMAP_000064
LOPAC0_000090
2,3-butanedione monoxime
2,3-butanedione oxime
2, monoxime
2, monooxime
diacetyl monoxime
2-oximino-3-butanone
2,3-butanedione monooxime
57-71-6
2,3-butanedione 2-oxime
DAM ,
diacetylmonooxime
biacetyl monooxime
wln: qnuy1&v1
biacetyl monoxime
nsc-116103
3-oximino-2-butanone
2,3-butanedione 3-monoxime
nsc116103
2,3-butanedione-2-monoxime
diacetyl monooxime
ccris 6215
brn 0605582
einecs 200-348-5
3-oxo-2-butanone oxime
nsc 116103
dam (oxime)
isonitrosoethyl methyl ketone
ai3-23962
nsc-660
C07509
diacetylmonoxime
nsc660
BDM ,
2,3-butanedione 2-monoxime
(2e)-butane-2,3-dione oxime
NCGC00024887-02
NCGC00024887-03
NCGC00024887-04
2,3-butanedione monoxime, >=98%
B 0753
inchi=1/c4h7no2/c1-3(5-7)4(2)6/h7h,1-2h3/b5-3+
NCGC00024887-05
fseupudheblwjy-hwkanzrosa-
chebi:4480 ,
bdbm50024959
chembl1255578 ,
(3e)-3-hydroxyimino-2-butanone
A831569
HMS3260A22
(3e)-3-hydroxyiminobutan-2-one
AKOS005207181
CCG-204185
S3699
2,3-butanedione, 2-oxime
4-01-00-03646 (beilstein handbook reference)
nsc 660
3-(hydroxyimino)butan-2-one
SCHEMBL282899
SCHEMBL257234
19SQ93LM6H ,
17019-25-9
2,3-butanedione, monooxime, (2e)-
2,3-butanedione, monooxime, (e)-
2,3-butanedione, 2-oxime, (2e)-
tox21_500090
NCGC00260775-01
W-105446
J-610059
110828-81-4
unii-19sq93lm6h
mfcd00002116
(z)-3-(hydroxyimino)butan-2-one
2,3-butanedione monoxime, 97%
2,3-butanedione monoxime, for spectrophotometric det. of urea, >=99.0%
(3e)-3-(hydroxyimino)butan-2-one
AS-58741
2,3-butanedione monoxime, p.a., 99.0%
sr-01000075306
SR-01000075306-1
SR-01000075306-3
(e)-3-(hydroxyimino)butan-2-one
CS-0015129
Q63392903
SDCCGSBI-0050078.P002
NCGC00024887-07
biacetylmonooxime
2, 3-BUTANEDIONE MONOOXIME
HY-Y0413
(3z)-3-(hydroxyimino)butan-2-one
2,3-butanedione, monooxime, (z)-
biacetyl monoxime;diacetyl monoxime;dam
2-3-butanedione monoxime
EN300-103351
Z1954805325

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were made for each of the additives (n> or =4 for each dose)."( Improving the preservation of isolated rat skeletal muscles stored for 16 hours at 4 degrees C.
Bär, DP; de Smet, M; de With, MC; Kon, M; Kroese, AB; van der Heijden, EP; Werker, PM, 2000
)
0.31
" Intravitreal injection of cytochalasin B inhibited NF axonal transport in optic axons in a dose-response manner."( Neurofilament transport is dependent on actin and myosin.
Chylinski, TM; Jung, C; Ortiz, D; Pimenta, A; Shea, TB, 2004
)
0.32
" Dose-response curves to the Ca(2+) ionophore A-23187 and to the calmodulin/myosin light chain kinase inhibitor W-7 served to study Ca(2+)-dependent pathways."( Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine.
Bisschops, R; Cassiman, D; Fevery, J; Laleman, W; Nevens, F; Roskams, T; Severi, T; Van Landeghem, L; Van Pelt, J; Vander Elst, I; Zeegers, M, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.23870.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency3.66110.004110.890331.5287AID493107
arylsulfatase AHomo sapiens (human)Potency1.06911.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.59730.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.12590.010039.53711,122.0200AID1479
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency0.07570.425612.059128.1838AID504536
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
neuropeptide S receptor isoform AHomo sapiens (human)Potency31.62280.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)Kd392.60000.00801.77505.3000AID1162636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1865777Reactivation of POX-inhibited human recombinant AChE assessed as reactivation rate constant using ATC as substrate at pH 10.5 and 17 degreeC followed by substrate addition by Ellman's method based spectrophotometry2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Dual acting oximes designed for therapeutic decontamination of reactive organophosphates
AID1162633Dissociation constant, pKa of the compound by Albert and Sergeant/UV-visible spectrophotometry method2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Assessment of antidotal efficacy of cholinesterase reactivators against paraoxon: In vitro reactivation kinetics and physicochemical properties.
AID1162635Octanol-phosphate buffer lipophilicity, log P of the compound at pH 7.6 after 24 hrs by shake flask method2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Assessment of antidotal efficacy of cholinesterase reactivators against paraoxon: In vitro reactivation kinetics and physicochemical properties.
AID1865776Reactivation of POX-inhibited human recombinant AChE assessed as reactivation rate constant using ATC as substrate at pH 10.5 and 37 degreeC followed by substrate addition by Ellman's method based spectrophotometry2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Dual acting oximes designed for therapeutic decontamination of reactive organophosphates
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1865762Permeability of compound by PAMPA assay2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Dual acting oximes designed for therapeutic decontamination of reactive organophosphates
AID1162637Maximum reactivation of paraoxon-inhibited AChE (unknown origin)2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Assessment of antidotal efficacy of cholinesterase reactivators against paraoxon: In vitro reactivation kinetics and physicochemical properties.
AID1162636Binding affinity to paraoxon-inhibited AChE (unknown origin)2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Assessment of antidotal efficacy of cholinesterase reactivators against paraoxon: In vitro reactivation kinetics and physicochemical properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (495)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (9.29)18.7374
1990's231 (46.67)18.2507
2000's163 (32.93)29.6817
2010's44 (8.89)24.3611
2020's11 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.36 (24.57)
Research Supply Index6.25 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index65.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (1.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other509 (98.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]